Pathria P, Louis TL, Varner JA. Targeting tumor-associated macrophages in cancer. Trends Immunol. 2019;40(4):310–27.
Article
CAS
PubMed
Google Scholar
Aras S, Zaidi M. TAMeless traitors: macrophages in cancer progression and metastasis. Br J Cancer. 2017;117(11):1583–91.
Article
CAS
PubMed
PubMed Central
Google Scholar
Qiu X, et al. Tumor-associated macrophages: key players in triple-negative breast cancer. Front Oncol. 2022;12: 772615.
Article
PubMed
PubMed Central
Google Scholar
Fu LQ, et al. The roles of tumor-associated macrophages in tumor angiogenesis and metastasis. Cell Immunol. 2020;353: 104119.
Article
CAS
PubMed
Google Scholar
Chen Y, et al. Targeting tumor-associated macrophages: a potential treatment for solid tumors. J Cell Physiol. 2020;236:3445–65.
Article
CAS
PubMed
Google Scholar
Ceci C, et al. Targeting tumor-associated macrophages to increase the efficacy of immune checkpoint inhibitors: a glimpse into novel therapeutic approaches for metastatic melanoma. Cancers (Basel). 2020;12(11):3401.
Article
CAS
Google Scholar
Mantuano NR, et al. Emerging role of glycosylation in the polarization of tumor-associated macrophages. Pharmacol Res. 2019;146: 104285.
Article
CAS
PubMed
Google Scholar
Li XF, Jolly M, George JT, Pienta KJ, Levine H. Computational modeling of the crosstalk between macrophage polarization and tumor cell plasticity in the tumor microenvironment. Front Oncol. 2019;9:10–21.
Article
PubMed
PubMed Central
Google Scholar
Dwyer AR, Greenland E, Pixley FJ. Promotion of tumor invasion by tumor-associated macrophages: the role of CSF-1-activated phosphatidylinositol 3 kinase and src family kinase motility signaling. Cancers (Basel). 2017;9(6):68–82.
Article
CAS
Google Scholar
Ludwig N, et al. Potential roles of tumor cell- and stroma cell-derived small extracellular vesicles in promoting a pro-angiogenic tumor microenvironment. Cancers (Basel). 2020;12(12):3599.
Article
CAS
Google Scholar
Zhu L, et al. Exosomal microRNAs induce tumor-associated macrophages via PPARγ during tumor progression in SHH medulloblastoma. Cancer Lett. 2022;535: 215630.
Article
CAS
PubMed
Google Scholar
Shinohara H, Kuranaga Y, Kumazaki M, Sugito N, Yoshikawa Y, Takai T, Taniguchi K, Ito Y, Akao Y. Regulated polarization of tumor-associated macrophages by miR-145 via colorectal cancer-derived extracellular vesicles. J Immunol. 2017;199(4):1505–15.
Article
CAS
PubMed
Google Scholar
Cooks T, Pateras I, Jenkins LM, Patel KM, Robles AI, Morris J, Forshew T, Appella E, Gorgoulis VG, Harris CC. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat Commun. 2018;9(1):771–85.
Article
CAS
PubMed
PubMed Central
Google Scholar
Frank AC, Ebersberger S, Fink AF, Lampe S, Weigert A, Schmid T, Ebersberger I, Syed SN, Brune B. Apoptotic tumor cell-derived microRNA-375 uses CD36 to alter the tumor-associated macrophage phenotype. Nat Commun. 2019;10(1):1135–52.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ludwig N, et al. Tumor-derived exosomes promote angiogenesis via adenosine A2B receptor signaling. Angiogenesis. 2020;23(4):599–610.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liu J, et al. Autophagy-dependent ferroptosis: machinery and regulation. Cell Chem Biol. 2020;27(4):420–35.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liu T et al. Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance. Neuro Oncol. 2022.
Dai E, Han L, Liu J, Xie Y, Kroemer G, Klionsky DJ, Zeh HJ, Kang R, Wang J, Tang D. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy. 2020;16:1–15.
Article
CAS
Google Scholar
Wu JY, Huang T, Hsieh YT, Wang YF, Yen CC, Lee GL, Yeh CC, Peng YJ, Kuo YY, Wen HT, Lin HC, Hsiao CW, Wu KK, Kung HJ, Hsu YJ, Kun CC. Cancer-derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor. Mol Cell. 2020;77(2):213-227e5.
Article
CAS
PubMed
Google Scholar
Novitskiy SV, et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood. 2008;112(5):1822–31.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang J et al. Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma. J Hepatol. 2020.
Li D, Ji H, Niu X, Yin L, Wang Y, Gu Y, Wang J, Zhou X, Zhang H, Zhang Q. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer. Cancer Sci. 2020;111(1):47–58.
Article
CAS
PubMed
Google Scholar
Radharani N, et al. Tumor-associated macrophage derived IL-6 enriches cancer stem cell population and promotes breast tumor progression via Stat-3 pathway. Cancer cell Int. 2022;22(1):122.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kong L, Zhou Y, Bu H, Lv T, Shi Y, Yang J. Deletion of interleukin-6 in monocytes/macrophages suppresses the initiation of hepatocellular carcinoma in mice. J Exp Clin Cancer Res. 2016;35(1):131–41.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang L, Dong Y, Li Y, Wang D, Liu S, Wang D, Gao Q, Ji S, Chen X, Lei Q, Jiang W, Wang L, Zhang B, Yu JJ, Zhang Y. IL-10 derived from M2 macrophage promotes cancer stemness via JAK1/STAT1/NF-κB/Notch1 pathway in non-small cell lung cancer. Int J Cancer. 2019;145(4):1099–110.
Article
CAS
PubMed
Google Scholar
Tsui YM, Chan LK, Ng IO. Cancer stemness in hepatocellular carcinoma: mechanisms and translational potential. Br J Cancer. 2020;122(10):1428–40.
Article
PubMed
PubMed Central
Google Scholar
Wei R, et al. S100 calcium-binding protein A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma. Int J Cancer. 2020;148:1233.
Article
CAS
PubMed
Google Scholar
Najafi M, Farhood B, Mortezaee K. Extracellular matrix (ECM) stiffness and degradation as cancer drivers. J Cell Biochem. 2019;120(3):2782–90.
Article
CAS
PubMed
Google Scholar
Lim GJ, Kang S, Lee JY. Novel invasion indices quantify the feed-forward facilitation of tumor invasion by macrophages. Sci Rep. 2020;10(1):718–27.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lee S, Lee E, Ko E, Ham M, Lee HM, Kim ES, Koh M, Lim HK, Jung J, Park SY, Moon A. Tumor-associated macrophages secrete CCL2 and induce the invasive phenotype of human breast epithelial cells through upregulation of ERO1-alpha and MMP-9. Cancer Lett. 2018;437:25–34.
Article
CAS
PubMed
Google Scholar
Gao L, Zhong W, Zhong WQ, Liu ZJ, Li HM, Yu ZL, Zhao YF. Tumor associated macrophages induce epithelial to mesenchymal transition via the EGFR/ERK1/2 pathway in head and neck squamous cell carcinoma. Oncol Rep. 2018;40(5):2558–72.
CAS
PubMed
PubMed Central
Google Scholar
Samaniego R, Gutierre-Gonzalez A, Gutierrez-Seijo A, Sanchez-Gregorio S, Garcia-Gimenez J, Mercader E, Marquez-Rodas I, Aviles JA, Relloso M, Sanchez-Mateos P. CCL20 expression by tumor-associated macrophages predicts progression of human primary cutaneous melanoma. Cancer Immunol Res. 2018;6(3):267–75.
Article
CAS
PubMed
Google Scholar
Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the Hallmarks of cancer. Cancer Cell. 2018;34(1):21–43.
Article
CAS
PubMed
Google Scholar
Feng R, et al. Nrf2 activation drive macrophages polarization and cancer cell epithelial–MESENCHYMAL transition during interaction. Cell Commun Signal. 2018;16(1):54.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mi X, et al. M2 macrophage-derived exosomal lncRNA AFAP1-AS1 and MicroRNA-26a affect cell migration and metastasis in esophageal cancer. Mol Ther Nucleic Acids. 2020;22:779–90.
Article
CAS
PubMed
PubMed Central
Google Scholar
Geng Y et al. A Notch-dependent inflammatory feedback circuit between macrophages and cancer cells regulates pancreatic cancer metastasis. Cancer Res. 2020.
Hwang I, et al. Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients. J Transl Med. 2020;18(1):443.
Article
CAS
PubMed
PubMed Central
Google Scholar
James WO, Joanne EA, Isaac D, Emily JH et al. Macrophages orchestrate the expansion of a proangiogenic perivascular niche during cancer progression. Sci Adv. 2021.
Kabasawa T, et al. Potential role of M2 TAMs around lymphatic vessels during lymphatic invasion in papillary thyroid carcinoma. Sci Rep. 2021;11(1):1150.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang Y, Chang T, Wu T, Xu W, Dou G, Wang Y, Guo C. M2 macrophages promote vasculogenesis during retinal neovascularization by regulating bone marrow-derived cells via SDF-1/VEGF. Cell Tissue Res. 2020;380:469–86.
Article
CAS
PubMed
Google Scholar
Britto DD et al. Macrophages enhance Vegfa-driven angiogenesis in an embryonic zebrafish tumour xenograft model. Dis Model Mech. 2018;11(12).
Yang Y, et al. M2 macrophage-derived exosomes promote angiogenesis and growth of pancreatic ductal adenocarcinoma by targeting E2F2. Mol Ther. 2020;29:1226.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wenes M, Shang M, Di Matteo M, Goveia J, Martin-Perez R, Serneels J, Prenen H, Ghesquiere B, Carmeliet P, Mazzone M. Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis. Cell Metab. 2016;24(5):701–15.
Article
CAS
PubMed
Google Scholar
Cheng N, et al. Targeting tumor-associated macrophages as an antitumor strategy. Biochem Pharmacol. 2020;183: 114354.
Article
CAS
PubMed
Google Scholar
Petty AJ, Li A, Wang X, Dai R, Heyman B, Hsu D, Huang X, Yang Y. Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment. J Clin Invest. 2019;129(12):5151–62.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sun W, Wei F, Li WJ, Wei JW, Zhong H, Wen YH, Lei WB, Chen L, Li H, Lin HQ, Iqbal M, Wen WP. A positive-feedback loop between tumour infiltrating activated Treg cells and type 2-skewed macrophages is essential for progression of laryngeal squamous cell carcinoma. Br J Cancer. 2017;117(11):1631–43.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887–904.
Article
CAS
PubMed
Google Scholar
Zhang H, et al. Poor clinical outcomes and immunoevasive contexture in intratumoral IL-10-producing macrophages enriched gastric cancer patients. Ann Surg. 2022;275(4):e626–35.
Article
PubMed
Google Scholar
Hensler M, et al. M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer. J Immunother Cancer. 2020;8(2):e000979.
Article
PubMed
PubMed Central
Google Scholar
Giatromanolaki A, et al. Expression of CD47 and SIRPalpha macrophage immune-checkpoint pathway in non-small-cell lung cancer. Cancers (Basel). 2022;14(7):1801.
Article
CAS
Google Scholar
Matlung HL, et al. The CD47-SIRPalpha signaling axis as an innate immune checkpoint in cancer. Immunol Rev. 2017;276(1):145–64.
Article
CAS
PubMed
Google Scholar
Veillette A, Tang Z. Signaling regulatory protein (SIRP)α-CD47 blockade joins the ranks of immune checkpoint inhibition. J Clin Oncol. 2019;37(12):1012–4.
Article
CAS
PubMed
Google Scholar
Wang H, et al. CD47/SIRPalpha blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy. J Immunother Cancer. 2020;8(2):e000905.
Article
PubMed
PubMed Central
Google Scholar
Xi Q, et al. Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity. J Immunother Cancer. 2020;8(1):e000253.
Article
PubMed
PubMed Central
Google Scholar
Kuo TC, et al. Targeting the myeloid checkpoint receptor SIRPalpha potentiates innate and adaptive immune responses to promote anti-tumor activity. J Hematol Oncol. 2020;13(1):160.
Article
CAS
PubMed
PubMed Central
Google Scholar
Anderson NR, et al. Macrophage-based approaches for cancer immunotherapy. Cancer Res. 2020;81:1201.
Article
PubMed
Google Scholar
Zhang L, et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J Hematol Oncol. 2020;13(1):153.
Article
CAS
PubMed
PubMed Central
Google Scholar
Klichinsky M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947–53.
Article
CAS
PubMed
PubMed Central
Google Scholar
Junankar S, Shay G, Jurczyluk J, Ali N, Down J, Pocock N, Parker A, Nguyen A, Sun S, Kashemirov B, McKenna CE, Croucher PI, Swarbrick A, Weilbaecher K, Phan TG, Rogers MJ. Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. Cancer Discov. 2015;5(1):35–42.
Article
CAS
PubMed
Google Scholar
Zang X, Zhang X, Hu H, Qiao M, Zhao X, Deng Y, Chen D. Targeted delivery of zoledronate to tumor-associated macrophages for cancer immunotherapy. Mol Pharm. 2019;16(5):2249–58.
Article
CAS
PubMed
Google Scholar
Sabatino R, Battistelli S, Magnani M, Rossi L. Preclinical evaluation of an innovative anti-TAM approach based on zoledronate-loaded erythrocytes. Drug Deliv Transl Res. 2018;8(5):1355–64.
Article
CAS
PubMed
Google Scholar
Scott EM, Jacobus E, Lyons B, Frost S, Freedman JD, Dyer A, Khalique H, Taverner WK, Carr A, Champion BR, Fisher KD, Seymour LW, Duffy MR. Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples. J Immunother Cancer. 2019;7(1):320–37.
Article
PubMed
PubMed Central
Google Scholar
Shih CT, et al. TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in non-small cell lung cancer via down-regulation of CSF-1R and enhances the anti-tumor effects of anti-PD-1. Cancer Lett. 2020;498:142.
Article
CAS
PubMed
Google Scholar
Wesolowski R et al. Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. Ther Adv Med Oncol. 2019;11.
Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martín-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, Van DSM, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. The Lancet. 2019;394(10197):478–87.
Article
CAS
Google Scholar
Liu YQ, et al. Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R. Acta Pharmacol Sin. 2018;39(11):1768–76.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kumar V, et al. Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell. 2017;32(5):654-668e5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Li X, et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2017;66(1):157–67.
Article
CAS
PubMed
Google Scholar
Nywening TM, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17(5):651–62.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cho HR, et al. Increased antiangiogenic effect by blocking CCL2-dependent macrophages in a rodent glioblastoma model: correlation study with dynamic susceptibility contrast perfusion MRI. Sci Rep. 2019;9(1):11085–96.
Article
CAS
PubMed
PubMed Central
Google Scholar
Flores-Toro JA, et al. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Proc Natl Acad Sci USA. 2020;117(2):1129–38.
Article
CAS
PubMed
Google Scholar
Jiang Y, et al. Targeting neddylation inhibits intravascular survival and extravasation of cancer cells to prevent lung-cancer metastasis. Cell Biol Toxicol. 2019;35(3):233–45.
Article
PubMed
Google Scholar
Zhou L, et al. Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-kappaB-CCL2 signaling in lung cancer. Oncogene. 2019;38(29):5792–804.
Article
CAS
PubMed
Google Scholar
Ao JY, et al. Colony-stimulating factor 1 receptor blockade inhibits tumor growth by altering the polarization of tumor-associated macrophages in hepatocellular carcinoma. Mol Cancer Ther. 2017;16(8):1544–54.
Article
CAS
PubMed
Google Scholar
Fujiwara T, et al. CSF1/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment. Mol Cancer Ther. 2021;20(8):1388–99.
Article
CAS
PubMed
Google Scholar
Peng X, et al. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models. J Exp Clin Cancer Res. 2019;38(1):372–87.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang Q, et al. Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma. Leukemia. 2018;32(1):176–83.
Article
CAS
PubMed
Google Scholar
Vidyarthi A, et al. TLR-3 stimulation skews M2 macrophages to M1 through IFN-αβ signaling and restricts tumor progression. Front Immunol. 2018;9:1650–63.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kapp K, et al. Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors. Oncoimmunology. 2019;8(12): e1659096.
Article
PubMed
PubMed Central
Google Scholar
Liu Z, et al. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages. Cancer Lett. 2020;469:173–85.
Article
CAS
PubMed
Google Scholar
Thomas M, et al. Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study. Ann Oncol. 2018;29(10):2076–84.
Article
CAS
PubMed
PubMed Central
Google Scholar
Oronsky B, et al. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opin Investig Drugs. 2017;26(1):109–19.
Article
CAS
PubMed
Google Scholar
Pedro C. RRx-001 acts as a dual small molecule checkpoint inhibitor by downregulating CD47 on cancer cells and SIRP-alpha on monocytes/macrophages. Transl Oncol. 2019;12(4):626–32.
Article
Google Scholar
Locatelli SL, et al. Targeting cancer cells and tumor microenvironment in preclinical and clinical models of hodgkin lymphoma using the dual PI3Kdelta/gamma inhibitor RP6530. Clin Cancer Res. 2019;25(3):1098–112.
Article
CAS
PubMed
Google Scholar
Li X, et al. Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat Rev Clin Oncol. 2020;17(11):657–74.
Article
PubMed
Google Scholar
Yang G, et al. Acceptor engineering for optimized ROS generation facilitates reprogramming macrophages to M1 phenotype in photodynamic immunotherapy. Angew Chem Int Ed Engl. 2020;60:5386.
Article
CAS
Google Scholar
Moradi-Chaleshtori M, et al. In vitro and in vivo evaluation of anti-tumoral effect of M1 phenotype induction in macrophages by miR-130 and miR-33 containing exosomes. Cancer Immunol Immunother. 2020;70:2313.
Google Scholar
Wang L, et al. Targeted delivery of miR-99b reprograms tumor-associated macrophage phenotype leading to tumor regression. J Immunother Cancer. 2020;8(2):e000517.
Article
PubMed
PubMed Central
Google Scholar
Eisinger S, et al. Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells. Proc Natl Acad Sci USA. 2020;117(50):32005–16.
Article
CAS
PubMed
PubMed Central
Google Scholar
La Fleur L, et al. Targeting MARCO and IL37R on immunosuppressive macrophages in lung cancer blocks regulatory T cells and supports cytotoxic lymphocyte function. Cancer Res. 2021;81(4):956–67.
Article
CAS
PubMed
Google Scholar
Georgoudaki A, et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep. 2016;15(9):2000–11.
Article
CAS
PubMed
Google Scholar
Liu W, et al. Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis. Cancer Lett. 2020;472:59–69.
Article
CAS
PubMed
Google Scholar
Wanderley CW, et al. Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner. Cancer Res. 2018;78(20):5891–900.
CAS
PubMed
Google Scholar
Mantovani A, et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399–416.
Article
CAS
PubMed
PubMed Central
Google Scholar
Salvagno C, et al. Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. Nat Cell Biol. 2019;21(4):511–21.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gomez-Roca CA, et al. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. Ann Oncol. 2019;30(8):1381–92.
Article
CAS
PubMed
PubMed Central
Google Scholar
Choi SH, et al. Tumour-vasculature development via endothelial-to-mesenchymal transition after radiotherapy controls CD44v6+ cancer cell and macrophage polarization. Nat Commun. 2018;9(1):5108–25.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rafat M, et al. Macrophages promote circulating tumor cell-mediated local recurrence following radiotherapy in immunosuppressed patients. Cancer Res. 2018;78(15):4241–52.
Article
CAS
PubMed
PubMed Central
Google Scholar
Brown JM, et al. Macrophage exclusion after radiation therapy (MERT): a new and effective way to increase the therapeutic ratio of radiotherapy. Radiother Oncol. 2019;144:159–64.
Article
CAS
PubMed
Google Scholar
Sumitomo R, et al. PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer. Lung Cancer. 2019;136:136–44.
Article
PubMed
Google Scholar
Wu Q, et al. Blocking triggering receptor expressed on myeloid cells-1-positive tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-programmed cell death ligand 1 resistance in liver cancer. Hepatology. 2019;70(1):198–214.
Article
CAS
PubMed
Google Scholar
Yin Y, et al. Colorectal cancer-derived small extracellular vesicles promote tumor immune evasion by upregulating PD-L1 expression in tumor-associated macrophages. Adv Sci (Weinh). 2022;9(9):2102620.
Article
CAS
Google Scholar
Yin Y, et al. Colorectal cancer-derived small extracellular vesicles promote tumor immune evasion by upregulating PD-L1 expression in tumor-associated macrophages. Adv Sci (Weinheim, Baden-Wurttemberg, Germany). 2022;9(9):2102620.
CAS
Google Scholar
Hartley GP, et al. Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation. Cancer Immunol Res. 2018;6(10):1260–73.
Article
CAS
PubMed
Google Scholar
Yang H, et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. Mol Cancer. 2020;19(1):41–54.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wu X, et al. A small molecule CCR2 antagonist depletes tumor macrophages and synergizes with anti-PD1 in a murine model of cutaneous T cell lymphoma (CTCL). J Invest Dermatol. 2020;140:1390.
Article
CAS
PubMed
Google Scholar
Li Z, et al. Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment. Nat Commun. 2022;13(1):1845.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang F, et al. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat Commun. 2019;10(1):3974–89.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rodell CB, et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat Biomed Eng. 2018;2(8):578–88.
Article
CAS
PubMed
PubMed Central
Google Scholar
Xiao H, et al. M2-Like tumor-associated macrophage-targeted codelivery of STAT6 inhibitor and IKKbeta siRNA induces M2-to-M1 repolarization for cancer immunotherapy with low immune side effects. ACS Cent Sci. 2020;6(7):1208–22.
Article
CAS
PubMed
PubMed Central
Google Scholar
Li CX, et al. Artificially reprogrammed macrophages as tumor-tropic immunosuppression-resistant biologics to realize therapeutics production and immune activation. Adv Mater. 2019;31(15): e1807211.
Article
CAS
PubMed
Google Scholar
Yang L, et al. Synergetic functional nanocomposites enhance immunotherapy in solid tumors by remodeling the immunoenvironment. Adv Sci (Weinh). 2019;6(8):1802012.
Article
CAS
Google Scholar
Papalexi E, Satija R. Single-cell RNA sequencing to explore immune cell heterogeneity. Nat Rev Immunol. 2018;18(1):35–45.
Article
CAS
PubMed
Google Scholar
Zhang L, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell. 2020;181(2):442-459e29.
Article
CAS
PubMed
Google Scholar
Song G, et al. Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression. Cell Discov. 2020;6(1):90.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cortese N, et al. Prognostic significance of tumor-associated macrophages: past, present and future. Semin Immunol. 2020;48: 101408.
Article
CAS
PubMed
Google Scholar